pharma · Leukemia, Lymphocytic, Acute, B-Cell · Prostate Cancer Indications
Shenzhen Second People's
Shenzhen Second People's Hospital
Shenzhen Second People's is a pharma organization headquartered in CN. Primary therapeutic focus areas include Leukemia, Lymphocytic, Acute, B-Cell, Prostate Cancer Indications. NovaPharmaNews links 2 clinical program(s)
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 4
- Patents
- 0
CART19 cell and auto-HSCT
Phase 1 · mab · Leukemia, Lymphocytic, Acute, B-Cell
CART19 cell and auto-HSCT for Leukemia, Lymphocytic, Acute, B-Cell is a Phase 1 program (mab) at Shenzhen Second People's Hospital with 1 ClinicalTrials.gov record(s).
Internal code Weihong Chen06062018
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shenzhen Second People's Hospital
- Phase
- Phase 1
- Modality
- mab
- Indication
- Leukemia, Lymphocytic, Acute, B-Cell
- Status
- active
- Trials
- 1